Patents by Inventor Kelly I. Guthrie

Kelly I. Guthrie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOACTIVE RENAL CELLS
    Publication number: 20210238600
    Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.
    Type: Application
    Filed: February 9, 2021
    Publication date: August 5, 2021
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric S. Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Jr., Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Bioactive renal cells
    Patent number: 11066666
    Abstract: The present invention concerns bioactive renal cells populations, renal cell constructs, and methods of making and using the same.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: July 20, 2021
    Assignee: inRegen
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • BIOACTIVE RENAL CELLS
    Publication number: 20180282726
    Abstract: The present invention concerns bioactive renal cells populations, renal cell constructs, and methods of making and using the same.
    Type: Application
    Filed: March 19, 2018
    Publication date: October 4, 2018
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darrell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Bioactive renal cells
    Patent number: 10077442
    Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: September 18, 2018
    Assignee: inRegen
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • Bioactive renal cells
    Patent number: 10030242
    Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: July 24, 2018
    Assignee: InRegen
    Inventors: Timothy A. Bertram, Roger M. Ilagan, Russell W. Kelley, Sharon C. Presnell, Sumana Choudhury, Andrew T. Bruce, Christopher W. Genheimer, Bryan R. Cox, Kelly I. Guthrie, Joydeep Basu, Shay M. Wallace, Eric Werdin, Oluwatoyin A. Knight, Namrata D. Sangha, John W. Ludlow, Craig R. Halberstadt, Richard Payne, Neil F. Robins, Darell McCoy, Deepak Jain, Manuel J. Jayo, Elias A. Rivera, Thomas Spencer, Benjamin Watts
  • CELL SCAFFOLD CONSTRUCTS
    Publication number: 20180071074
    Abstract: The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.
    Type: Application
    Filed: May 18, 2017
    Publication date: March 15, 2018
    Inventors: John W. Ludlow, Manuel J. Jayo, Joydeep Basu, Timothy A. Bertram, Christopher W. Genheimer, Kelly I. Guthrie, Roger M. Ilagan, Deepak Jain, Oluwatoyin A. Knight, Richard Payne, Sarah F. Quinlan, H. Scott Rapoport, Namrata D. Sangha
  • Cell scaffold constructs
    Patent number: 9271824
    Abstract: The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: March 1, 2016
    Assignee: REGENMEDTX, LLC
    Inventors: John W. Ludlow, Manuel J. Jayo, Joydeep Basu, Timothy A. Bertram, Christopher W. Genheimer, Kelly I. Guthrie, Roger M. Ilagan, Deepak Jain, Oluwatoyin A. Knight, Richard Payne, Sarah F. Quinlan, H. Scott Rapoport, Namrata D. Sangha
  • SMOOTH MUSCLE CELL CONSTRUCTS
    Publication number: 20150030657
    Abstract: The present invention relates to the regeneration, reconstruction, augmentation or replacement of luminal organs or tissue structures in a subject in need using scaffolds seeded with autologous or non-autologous cell populations that are or are not derived from the corresponding organ or tissue structure that is the subject of the regeneration, reconstruction, augmentation or replacement.
    Type: Application
    Filed: May 3, 2011
    Publication date: January 29, 2015
    Applicant: TENGION, INC.
    Inventors: John W. Ludlow, Manuel J. Jayo, Joydeep Basu, Timothy A. Bertram, Christopher W. Genheimer, Kelly I. Guthrie, Roger M. Ilagan, Deepak Jain, Oluwatoyin A. Knight, Richard Payne, Sarah F. Quinlan, H. Scott Rapoport, Namrata D. Sangha, Jacob E. Shokes, Teresa B. Burnette, Sarah A. Boyd, Craig R. Halberstadt, Dominic M. Justewicz, Elias A. Rivera, Wendy Sharp, Neil F. Robbins
  • CELL SCAFFOLD CONSTRUCTS
    Publication number: 20130173015
    Abstract: The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.
    Type: Application
    Filed: November 20, 2012
    Publication date: July 4, 2013
    Applicant: Tengion, Inc.
    Inventors: John W. Ludlow, Manuel J. Jayo, Joydeep Basu, Timothy A. Bertram, Christopher W. Genheimer, Kelly I. Guthrie, Roger M. Ilagan, Deepak Jain, Oluwatoyin A. Knight, Richard Payne, Sarah F. Quinlan, H. Scott Rapoport, Namrata D. Sangha
  • Cell-scaffold constructs
    Patent number: 8337485
    Abstract: The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: December 25, 2012
    Assignee: Tengion, Inc.
    Inventors: John W. Ludlow, Manuel J. Jayo, Joydeep Basu, Timothy A. Bertram, Christopher W. Genheimer, Kelly I. Guthrie, Roger M. Ilagan, Deepak Jain, Oluwatoyin A. Knight, Richard Payne, Sarah F. Quinlan, H. Scott Rapoport, Namrata D. Sangha
  • CELL-SCAFFOLD CONSTRUCTS
    Publication number: 20110224800
    Abstract: The present invention relates to the regeneration, reconstruction, augmentation or replacement of organs or tissue structures using scaffolds and cells derived from peritoneal tissue.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Inventors: John W. Ludlow, Kelly I. Guthrie, Andrew T. Bruce, Kenny Johnson
  • Cell-Scaffold Constructs
    Publication number: 20100131075
    Abstract: The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 27, 2010
    Inventors: John W. Ludlow, Manuel J. Jayo, Joydeep Basu, Timothy A. Bertram, Christopher W. Genheimer, Kelly I. Guthrie, Roger M. Ilagan, Deepak Jain, Oluwatoyin A. Knight, Richard Payne, Sarah F. Quinlan, H. Scott Rapoport, Namrata D. Sangha
  • DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids
    Patent number: 7297784
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: November 20, 2007
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6656906
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 2, 2003
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Publication number: 20030186874
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Application
    Filed: January 24, 2003
    Publication date: October 2, 2003
    Applicant: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6562787
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: May 13, 2003
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6348568
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: February 19, 2002
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6258782
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: July 10, 2001
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert